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Abstract: PURPOSE Several studies have demonstrated the negative impact of radiotherapy protocol
deviations on tumor control in medulloblastoma. In the SIOP PNET5 MB trial, a pretreatment ra-
diotherapy quality control (RT-QC) program was introduced. A first analysis for patients enrolled in
Germany, Switzerland and Austria with focus on types of deviations in the initial plan proposals and
review criteria for modern radiation technologies was performed. METHODS AND PATIENTS Sixty-
nine craniospinal irradiation (CSI) plans were available for detailed analyses. RT-QC was performed
according to protocol definitions on dose uniformity. Because of the lack of definitions for high-precision
3D conformal radiotherapy within the protocol, additional criteria for RT-QC on delineation and cov-
erage of clinical target volume (CTV) and planning target volume (PTV) were defined and evaluated.
RESULTS Target volume (CTV/PTV) deviations occurred in 49.3% of initial CSI plan proposals (33.3%
minor, 15.9% major). Dose uniformity deviations were less frequent (43.5%). Modification of the RT
plan was recommended in 43.5% of CSI plans. Unacceptable RT plans were predominantly related to
incorrect target delineation rather than dose uniformity. Unacceptable plans were negatively correlated
to the number of enrolled patients per institution with a cutoff of 5 patients (p = 0.001). CONCLU-
SION This prospective pretreatment individual case review study revealed a high rate of deviations and
emphasizes the strong need of pretreatment RT-QC in clinical trials for medulloblastoma. Furthermore,
the experiences point out the necessity of new RT-QC criteria for high-precision CSI techniques.
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Abstract
Purpose Several studies have demonstrated the negative impact of radiotherapy protocol deviations on tumor control
in medulloblastoma. In the SIOP PNET5 MB trial, a pretreatment radiotherapy quality control (RT-QC) program was
introduced. A first analysis for patients enrolled in Germany, Switzerland and Austria with focus on types of deviations in
the initial plan proposals and review criteria for modern radiation technologies was performed.
Beate Timmermann and Rolf-Dieter Kortmann share last
authorship.
Data sharing statementResearch data are stored in an institutional
repository and will be shared upon request to the corresponding
author.
Electronic supplementary material The online version of this
article (https://doi.org/10.1007/s00066-020-01707-8) contains
supplementary material, which is available to authorized users.
 Dr. med. Stefan Dietzsch, MD
stefan.dietzsch@medizin.uni-leipzig.de
1 Department for Radiation Oncology, University of Leipzig
Medical Center, Stephanstr. 9a, 04103 Leipzig, Germany
2 Departement of Pediatric Hematology and Oncology,
University Medical Center Hamburg-Eppendorf, Hamburg,
Germany
3 Clinic for Particle Therapy, West German Proton Therapy
Centre, University of Essen, Essen, Germany
4 Faculty of Medicine, Department of Radiation Oncology,
University of Cologne, Cologne, Germany
5 Department of Radiation Oncology, University Medical
Center Hamburg-Eppendorf, Hamburg, Germany
6 Department of Radiotherapy and Radiation Oncology,
Ludwig Maximilian University Munich, Munich, Germany
7 Center for Protontherapy, Paul Scherrer Institute, Villigen,
Switzerland
8 Department of Radiotherapy and Radiation Oncology,
Hospital Bremen Mitte, Bremen, Germany
9 Department of Radiotherapy and Radiation Oncology,
Faculty of Medicine and University Hospital Carl Gustav
Carus, Technical University Dresden, Dresden, Germany
10 Department of Radiation Oncology, Medical Faculty Heinrich
Heine University Duesseldorf, Duesseldorf, Germany
11 Department of Radiation Oncology and Radiotherapy,
Heidelberg University Hospital, Heidelberg, Germany
12 Radiation Oncology, Munich-Schwabing Municipal Hospital,
Munich, Germany
13 Department of Radiotherapy, University of Wuerzburg,
Wuerzburg, Germany
14 Department of Radiotherapy, Medical University of Vienna,
Vienna, Austria
15 Division of Pediatric Hematology/Oncology, Department of
Pediatrics and Adolescent Medicine, Medical University of
Graz, Graz, Austria
16 University Children’s Hospital of Zurich, Zurich, Switzerland
K
Strahlenther Onkol
Methods and patients Sixty-nine craniospinal irradiation (CSI) plans were available for detailed analyses. RT-QC was
performed according to protocol definitions on dose uniformity. Because of the lack of definitions for high-precision 3D
conformal radiotherapy within the protocol, additional criteria for RT-QC on delineation and coverage of clinical target
volume (CTV) and planning target volume (PTV) were defined and evaluated.
Results Target volume (CTV/PTV) deviations occurred in 49.3% of initial CSI plan proposals (33.3% minor, 15.9%
major). Dose uniformity deviations were less frequent (43.5%). Modification of the RT plan was recommended in 43.5%
of CSI plans. Unacceptable RT plans were predominantly related to incorrect target delineation rather than dose uniformity.
Unacceptable plans were negatively correlated to the number of enrolled patients per institution with a cutoff of 5 patients
(p= 0.001).
Conclusion This prospective pretreatment individual case review study revealed a high rate of deviations and emphasizes
the strong need of pretreatment RT-QC in clinical trials for medulloblastoma. Furthermore, the experiences point out the
necessity of new RT-QC criteria for high-precision CSI techniques.
Keywords Quality assurance · Deviation · Brain tumor · Pediatric · Review criteria
Introduction
In standard risk (SR) medulloblastoma, craniospinal irradi-
ation (CSI) followed by a tumor bed boost is considered the
standard treatment in non-infant age groups. Retrospective
reports showed that inadequate treatment fields had a nega-
tive impact on tumor control and outcome [1–3]. This was
confirmed in similar clinical settings [4–6]. Thus, there is
a broad consensus that pretreatment quality control of ra-
diotherapy plans (RT-QC) is an important measure in multi-
institutional clinical trials [7–10].
In 2014, the European branch of the International So-
ciety of Pediatric Oncology (SIOPe) initiated the SIOP
PNET5 MB trial for children with non-metastatic medul-
loblastoma with a low-risk or average-risk biological profile
(ClinicalTrials.gov identifier: NCT02066220). The quality
assurance (QA) program included a central review of
Fig. 1 Workflow and time
schedule for quality control from
surgery to start of radiotherapy.
MRI Magnetic resonance imag-
ing, CSF cerebrospinal fluid,
RT radiotherapy, RT-QC quality

































































pathology, magnetic resonance imaging (MRI), and ra-
diotherapy (RT). Furthermore, pretreatment RT-QC was
considered a mandatory component of the study. This
report describes a first analysis for patients enrolled in Ger-
many, Austria, and Switzerland, with focus on the type of
deviations in the initial plan proposals and review criteria
for modern radiation technologies.
Materials andmethods
SIOP PNET5 MB is a prospective phase II/III study in pa-
tients between the ages of 3 to 5 years and 21 years with
clinical SR medulloblastomas according to the risk group
definitions which have been used so far, e.g., in HIT-SIOP
PNET4 [11–13]. Patients with low-risk biological profile
(PNET5 MB, LR arm) received 18Gy to the craniospinal
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Table 1 SIOP PNET5 protocol definitions of radiotherapy parameters for quality control and additional definitions of target delineation as minor
or major deviation of the reference center
Per protocol Minor deviation Major deviation
Protocol definitions
Target volume
CSI (distance from field edge to CTV)
Cribriform
plate
≥5mm 3 to <5mm <3mm
All other
regions
≥10mm 5 to <10mm <5mm
Dose uniformity
V95% ≥95% ≥90 to <95% <90%
V107% ≤5% >5% to <10% ≥10%
Additional definitions by the reference center
Target volume delineation
CTV/PTV Entire subarachnoid space encom-
passed by PTV and CTV
Entire subarachnoid space not encom-
passed by CTV but by PTV
Entire subarachnoid space not encom-
passed by CTV and PTV
CSI Craniospinal irradiation, CTV clinical target volume, PTV planning target volume, V95% proportion of PTV which is covered by the 95%
isodose, V107% proportion of PTV which receive ≥107% of the prescribed dose
axis. All other SR patients (PNET5 MB, SR arm) received
23.4Gy CSI. The tumor site was boosted up to 54Gy. Pa-
tients recruited to the SIOP PNET5 MB SR and LR strata
until December 31, 2018 in Germany, Switzerland and Aus-
tria and with complete available DICOM-RT data of CSI
plans were considered eligible for this report.
RT-QC was performed by the Reference Center for Ra-
diotherapy in Childhood Brain Tumors in Leipzig in col-
laboration with the West German Proton Center in Essen.
Workflow and time schedule of RT-QC are shown in Fig. 1.
A benchmark case or dummy run was not performed. All lo-
cal radiation oncologists received a detailed individualized
treatment recommendation including target delineation and
dosimetric aims. Central plan analyses were performed by
importing the original plan data including dose files into
the local treatment planning systems of the reference cen-
ters (RayStation, Raysearch Laboratories, Stockholm, Swe-
den). CSI techniques were documented and grouped into
three categories: 3D conformal (lateral opposing fields for
brain and posterior fields for spine), high precision photon
(intensity-modulated radiotherapy with fixed gantry angles
[IMRT], volumetric modulated arc therapy [VMAT], to-
motherapy), or proton beam therapy (with active scanning).
Typical dose distributions are available in the supplemen-
tary material (Fig. S1). In order to analyze possible changes
during accrual, time of enrollment was divided in two peri-
ods. Cut-off was the median of enrolled patients at the end
of 2016.
For SIOP PNET5 MB RT-QC, minor and major de-
viations of dose uniformity were defined according to
ICRU 50/62 (Table 1; [14, 15]). Target deviations were
used according to Carrie et al. [1]. These definitions ad-
dress the distance from the field edge to the clinical target
volume (CTV) and are therefore only suitable for simula-
tion-based treatment planning and 3D conformal techniques
with opposing lateral fields of the brain and posterior fields
of the spinal axis. For high-precision CSI techniques, RT-
QC adaptations of the former concept described by Car-
rie et al. were performed in order to better evaluate the
CTV/PTV and their coverage by the 95% isodose, with
a special focus on the critical areas cribriform plate, tem-
poral lobe, and thecal sac (Table 1; [1]). Since 2018, CTV
has been evaluated according to the SIOP guideline on
craniospinal target volume delineation with additional spe-
cial focus on skull base foramina [16]. The SIOP PNET5
MB protocol required contouring of organs at risk (OAR)
and collection of corresponding dose exposure. 30Gy to at
least one cochlea is the only dose constraint to an OAR.
Contouring and dose to OAR was not a criterion for plan
acceptance.
Furthermore, deviations were checked for clinical rele-
vance (expected increased risk for relapse and/or increased
risk for toxicity) and scored as “acceptable” or “unaccept-
able” at the discretion of the reviewer and based on the
experience of treatment plan evaluation in the SIOP Neu-
roblastoma protocol [17]. The overall QA result was rated
as “per protocol,” “acceptable deviation,” or “unacceptable
deviation.” If modifications were required, results of RT-
QC were communicated to the treating institution by tele-
phone and/or Email including illustrating screenshots. The
final result was subsequently communicated by a formal
letter.
Associations between variables were examined using χ2
tests. All statistical analyses were performed using the Sta-
tistical Package for Social Sciences (IBM SPSS statistics),
version 24 (IBM, Armonk, NY, USA).
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Fig. 2 Influence of experience
with protocol on quality control
result. n depicts number of pa-
tients who were evaluated with
respect to the patients in ra-
diotherapy unit (e.g., 24 patients
were evaluated as the first patient
















2nd 4th 5th 7th
or later
6th3rd
Patient in RT Unit
n=24 n=14 n=7 n=6 n=5 n=2 n=7
Results
Between September 2014 and December 2018, 70 German,
6 Swiss, and 2 Austrian patients were enrolled in the SIOP
PNET5-MB trial and treated in 29 institutions. In 8 pa-
tients, no DICOM-RT data were available. One patient was
treated by a simulation-based treatment technique. In this
patient, modification of RT portals at the cribriform plate
was recommended. The patient was excluded from analy-
sis because of the lack of CTV/PTV structures and dose
uniformity data. Sixty-nine CSI plans were available for
detailed evaluation. Forty-six patients (66.6%) were treated
in the SR arm and 23 patients (33.3%) in the LR arm. Sup-
plementary Table 1S summarizes the frequency of different
CSI techniques over the evaluated period. The data indicate
a shift from 3D conformal techniques being the most com-
mon between 2014 and 2016, to proton therapy being the
most common to date.
Supplementary Table S2 summarizes the frequency of
target volume and dose uniformity deviations in the initial
plan proposals. Target volume deviations occurred in 49.3%
of RT plans and were more frequent in the brain CTV/PTV
(30.4%) than in the spinal CTV/PTV (24.6%). Dose uni-
formity deviations were found in 43.5% of the RT plans
and were more frequent in the spinal PTV. The frequency
of dose uniformity deviation was higher for 3D conformal
radiotherapy (72.7% major, 22.7% minor) than for high-
precision techniques, in which 80.9% were per protocol (χ2
p< 0.001). Only 1 of 22 3D conformal radiotherapy plans
met the dose uniformity criteria of the protocol. For high-
precision techniques, the median V95 (proportion of PTV
which is covered by the 95% isodose) was 99.1%± 2% for
PTV-brain and 98.3%± 5.2% for PTV-spine. V107 (pro-
portion of PTV which receives ≥107% of the prescribed
dose) was median 0% for both PTVs.
Only 27 plans (39.1%) did not have any deviation. In
17.4% (n= 12) of the RT plans, deviations were considered
as acceptable and in 30 (43.5%) plan modifications were
recommended. The rate of recommended CSI plan mod-
ifications was higher in low-recruiting (≤4 patients) than
in high-recruiting (≥5 patients) radiotherapy units (62.1%
vs. 30%; χ2 p= 0.005). An impact of institutional experi-
ence in treating SIOP PNET5 MB trial patients on the rate
of unaccepted RT plans was also observed (Fig. 2). High
rates of unacceptable deviations were seen in the first 4 pa-
tients in all RT units. The rate declined when enrolling the
fifth and following patients (first to fourth patient in unit
56.9% vs. fifth or later patient in unit 5.6%; χ2 p< 0.001).
The percentage of recommended CSI plan modifications
did not decrease over time and was 44.1% in 2014–2016
and 42.9% in 2017–2018 (χ2 p= 0.916).
Table 2 shows the interaction between the type of devi-
ation and requirement of RT plan modification. Only 1 RT
plan with dose uniformity deviation alone required plan
modification. In 9 of 30 (30%) cases with unacceptable de-
viations, only target volume deviations were present, with
a correct assessment of dose uniformity. 20 of 30 unaccept-
able plans showed both types of deviation.
Discussion
The present study represents a large cohort of a pretreat-
ment, fully digital individual case review RT-QC procedure
in medulloblastomas treated by CSI.
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Table 2 Interaction between target and dose uniformity deviations with respect to overall result (acceptable/unacceptable) of the initial plan
proposals of the local radiation oncologist
Per protocol Acceptable deviation Unacceptable deviation Total
Correct target and dose 27 0 0 27

























Total 27 12 30 69
Observed deviations
We observed a high rate of RT protocol deviations in the
initial plan proposals (49.3% target delineation, 43.5% dose
uniformity). 30 of 69 (43.5%) RT plans were clinically
unacceptable and modifications were recommended. High
rates of RT protocol deviations were also reported in other
medulloblastoma trials. Most of these retrospective studies
were based on the evaluation of simulation films of lateral
opposing fields for the brain and posterior fields for the
spinal canal [1, 2, 18, 19]. First experiences of pretreat-
ment central RT-QC of SIOP PNET5 MB patients treated
in Italy revealed a necessity of plan revision in 62.5% of
CSI plans. Most common reasons were target delineation
and covering of the cribriform plate or the thecal sac [20].
CTV/PTV delineation
Definitions of targeting deviations in the SIOP PNET5 MB
protocol adopted the QC process of the HIT-SIOP PNET4
trial or Carrie et al., respectively [1, 12]. This included
the distance from the field edge and bony reference struc-
tures to the CTV in lateral opposing fields for the brain and
dorsal fields for the spinal canal. The use of this technique,
however, decreased from approximately 50% in 2014–2016
to 14% in 2017–2018. Modern high-precision technologies
(IMRT, VMAT, tomotherapy, and in particular proton beam
therapy) were increasingly used to decrease the risk of late
toxicity and can be considered as standard of care today
[21–24]. Presently, there is no established standardized def-
inition of CSI targeting deviations for high-precision CSI
techniques available. However, both review of target de-
lineation and assessment of dose uniformity are indispens-
able for evaluating a treatment plan for any risk of relapse.
This necessity is emphasized by our findings that target
deviations were more common than dose uniformity devi-
ations in the 30 plans considered as “unacceptable” (3.3%
unacceptable dose uniformity alone, 30% unacceptable tar-
get definition alone, 66.7% both deviations). Similar results
were observed in the Italian cohort [20]. Moreover, 9 of our
69 plans (13%) or 9 of 30 unacceptable deviations (30%)
would have been scored as acceptable based on the dose
uniformity criteria alone defined in the protocol.
Dose uniformity and regional dose distribution
Evaluation of dose uniformity deviations has three short
comings. In case of posterior treatment fields, major devi-
ations can occur due to a formal underdosage in anterior
parts or overdosage in posterior parts of the spinal PTV.
This can especially be the case when the whole vertebral
bodies are included into the spinal PTV to prevent a dose
gradient >5Gy or >70% within the vertebral bodies [25].
These deviations, when caused by radiation techniques but
not due to planning inadequacies, were judged as acceptable
deviations not requiring any modification.
The V95% constraint has to be used with caution in
the case of large PTVs. The volume of PTV-brain varies
depending on age and is more than 1000cm3. The con-
straint V95%≥ 95% for a PTV of 1000cm3 means that un-
derdosages in 50cm3 will still be considered as per protocol.
The cribriform plate has been demonstrated to be a critical
region for relapse in medulloblastoma [1, 3, 26]. Because
of the small volume circumscribed, marked underdosage
can occur, although formally, a correct dose uniformity was
calculated. Therefore, regional dose distribution has to be
evaluated, especially in critical regions like the cribriform
plate or temporal lobes (Fig. 3).
Furthermore, the circumscribed regional dose distribu-
tion should be evaluated in regions of inadequate CTV and
PTV delineation. In our cohort, five cases of inadequate
CTV were identified not including the skull base foramina.
But for technical reasons, this region was encompassed by















Fig. 3 Examples of proposed deviations. a Acceptable deviation—the subarachnoid space according SIOP guideline (yellow)[16] is not encom-
passed by CTV (pink) but by the PTV (red). b Background for acceptable deviation in (a)—the distance from field edge (leaf) and 50% isodose
(light blue, as equivalent to a customized block) to the PTV (red) is 5mm (purple) and to the subarachnoid space (correct reference CTV; yellow)
approximately 8mm (brown), which is per protocol according to the SIOP PNET5 protocol definitions in Table 1. The 95% isodose does not
completely cover the PTV (red) but the subarachnoid space (yellow). c Major/unacceptable deviation—the subarachnoid space (thecal sac) is not
encompassed by CTV (pink) and PTV (red). d Unacceptable circumscribed regional dose in case of correct target definition and dose unifor-
mity—the subarachnoid space (cribriform plate) is encompassed by CTV (pink) and PTV (red) but the 95% isodose does not cover this critical
region because of eye-sparing plan optimization. e Acceptable plan in case of unacceptable target volume deviation—the subarachnoid space
(scull base foramina; violet) is not encompassed by CTV (pink) and PTV (red) but is covered by the 95% isodose (outer light green line) due to
radiation technique. SIOP International Society of Paediatric Oncology, CTV clinical target volume, PTV planning target volume, CSI craniospinal
irradiation
was judged as acceptable without requiring any modifica-
tion (Fig. 3).
As a consequence, major deviations were not automati-
cally unacceptable. On the other hand, a plan with formally
correct dose uniformity could be unacceptable, e.g., because
of inadequate CTV delineation or dose coverage at critical
regions. Due to these observations, it seems to be necessary
to renew the criteria for CSI-QC and to define acceptable
and unacceptable deviations.
New QC criteria
From our experience, we would propose defining differ-
ent criteria for 3D conformal plans (lateral opposing fields
for brain and posterior fields for spine) and high-precision
CSI techniques. QC of 3D conformal plans can be based
on the criteria of Carrie et al. [1]. The dose uniformity
criteria can be used for PTV-brain but seem to be unsuit-
able for the spinal PTV when covered by posterior spinal
fields. For high-precision techniques, we propose the new
criteria shown in Table 3 and illustrated in Fig. 3, which in-
clude CTV/PTV contouring, circumscribed regional dose,
vertebral dose in children before the end of the pubertal
acceleration phase [25], and dose uniformity. The basis of
RT-QC criteria is dose coverage of the entire subarachnoid
space defined according to the SIOP contouring guideline
[16]. CTV delineation according to this guideline is strongly
recommended. The criteria for CTV/PTV delineation adopt
the margins between field edge and CTV of Carrie et al.
[1] and the SIOP PNET 4 protocol [12]. Due to the typi-
cal lateral dose gradient in photon therapy, approximately
50% of the prescribed dose is given at the field edge and
95% of dose is applied approximately 3 to 5mm distant to
the field edge within the target. Furthermore, we find ade-
quate dose uniformity in the majority of cases when high-
precision CSI techniques were used. Therefore, we propose
using a stricter dose uniformity constraint (V95%≥ 98%)
as was recommended by the ICRU 83 report for IMRT
techniques [27]. The same constraints should also be used
for proton plans, respecting the recommendations of the
ICRU 78 report [28].
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Table 3 Proposal for definitions of acceptable and unacceptable deviations and final result of quality control in craniospinal irradiation with
high-precision techniques
Acceptable deviation Unacceptable deviation
Target volume delineation
CTV/PTV Entire subarachnoid spacea not encompassed by CTV
but by PTV
or
PTV larger than necessary
(≤0.5cm areas with effect on OAR doseb ≤1.0cm
areas without effect on OAR doseb)
Entire subarachnoid spacea not encompassed by CTV and
PTV
or
PTV substantially larger than necessary
(>0.5cm areas with effect on OAR doseb >1.0cm areas
without effect on OAR doseb)
Circumscribed regional dose coverage at critical locations (cribriform plate, temporal lobes, skull base foramina, thecal sac)
95%-isodose Not defined Does not encompass entire subarachnoid spacea
Vertebral dose in children before end of pubertal acceleration phase
Anterior-posterior dose
gradient
Not defined >5Gy or 70%c
Dose uniformity
V95% ≥95 to <98% <95%
V107% >5% to <10% ≥10%
Final result of RT-QC
Per protocol
Acceptable deviation
(in individual cases, when missing part of target volume is covered by dose due to radiation technique, final result can be acceptable deviation
even in case of unacceptable target volume deviation)
Unacceptable deviation
CTV Clinical target volume, PTV planning target volume, OAR organ at risk, V95% proportion of PTV which is covered by the 95% isodose,
V107% proportion of PTV which receive ≥107% of the prescribed dose, RT-QC quality control of radiotherapy, SIOP International Society of
Paediatric Oncology
aCorrect reference CTV according SIOP guideline [16]
bFor example, eye globe, lens, thyroid, lung, heart, esophagus, kidney
caccording SIOP consensus recommendations [25]
Impact of experience with RT guidelines of the
protocol
The rate of unaccepted RT plans in our cohort depends on
the experience of the radiotherapy units in treating SIOP
PNET5 MB patients, with a cutoff of 5 patients per insti-
tution. A comparable impact on the institution’s familiarity
with the protocol was seen in RT-QC of meningioma in the
EORTC 22042-26042 trial [6]. Fewer deviations were ob-
served in RT plans from high-recruiting institutions (≥5 pa-
tients) compared to those from low-recruiting centers (22%
vs. 62%, p= 0.007). The recently published Italian expe-
rience of SIOP PNET5 MB RT-QC also showed a higher
rate of corrected major deviations in patients when treated
in less experienced centers (88.2%) compared to the whole
cohort (62.5%) [20]. Interestingly, a decrease in unaccept-
able RT plans over time was not observed. This could partly
be explained by the continuous high percentage of patients
included by low-recruiting radiotherapy units (≤4 patients;
47.1% in 2014–2016 and 37.1% in 2017–2018; p= 0.404).
Additionally, the number of new institutions starting re-
cruitment of patients (patient 1 to 4) remained high in the
second period (57.1%).
Our observations underline the fundamental role of up-
front RT-QC to ensure protocol-compliant RT and con-
firmed the findings of the M-SFOP 98 protocol. In this trial,
craniospinal fields were reviewed before the start of radio-
therapy. Major deviations were observed in 14 of 55 pa-
tients; 9 of these deviations were due to eye shielding and
8 of them were modified before RT start [29]. It remains to
be seen how far the recently published European guideline
for craniospinal CTV contouring will help to improve target
delineation [16]. Furthermore, a training program for local
radiation oncologists including benchmark cases and with
a final certification of investigators has to be considered.
Conclusion
This pretreatment individual case review study revealed
a high rate of protocol deviations and emphasizes the strong
need for pretreatment RT-QC in clinical trials on medul-
loblastoma, particularly in low-recruiting centers and for
approximately the first 5 patients of each RT institution.
Therefore, pretreatment QA programs are desirable to sup-
port decentralized treatment in multicenter trials. Moreover,
K
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our experiences point out the necessity of new RT-QC cri-
teria for high-precision CSI techniques.
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